BioLASCO Taiwan Co., Ltd. (TPEX:6662)
Taiwan
· Delayed Price · Currency is TWD 33.00
-0.35 (-1.05%)
May 2, 2025, 1:02 PM CST
BioLASCO Taiwan Revenue
In the year 2024, BioLASCO Taiwan had annual revenue of 292.50M TWD with 10.49% growth. BioLASCO Taiwan had revenue of 83.75M in the quarter ending December 31, 2024, with 2.27% growth.
Revenue
292.50M
Revenue Growth
+10.49%
P/S Ratio
2.89
Revenue / Employee
3.21M
Employees
91
Market Cap
845.20M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 292.50M | 27.78M | 10.49% |
| Dec 31, 2023 | 264.72M | 28.81M | 12.21% |
| Dec 31, 2022 | 235.91M | 8.33M | 3.66% |
| Dec 31, 2021 | 227.58M | -71.30M | -23.86% |
| Dec 31, 2020 | 298.88M | -47.81M | -13.79% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| PharmaEssentia | 9.73B |
| Caliway Biopharmaceuticals | 44.43M |
| Bora Pharmaceuticals Co., LTD. | 19.25B |
| Lotus Pharmaceutical | 18.58B |
| Oneness Biotech | 117.93M |
| Polaris Group | 107.00M |
| Lumosa Therapeutics | 39.15M |
| Pegavision | 6.82B |